Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma. Issue 8 (11th March 2019)

• Record Type: Journal Article
• Authors: Morse, Ryan T.; Ganju, Rohit G.; TenNapel, Mindi J.; Neupane, Prakash; Kakarala, Kiran; Shnayder, Yelizaveta; Chen, Allen M.; Lominska, Christopher E.
• Is Part Of: Head & neck. Volume 41:Issue 8(2019)
• Page Start: 2492
• Page End: 2499
• Publication Date: 2019-03-11
• Subjects: cisplatin -- concurrent -- head and neck -- radiation -- squamous cell carcinoma; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25717
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Triweekly high‐dose cisplatin (100 mg/m 2 ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m 2 with alternative weekly 40 mg/m 2 and weekly <40 mg/m 2 cisplatin regimens. Methods: From 2011 to 2016, 163 patients received concurrent cisplatin and intensity‐modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression‐free survival. Results: Cisplatin weekly <40 mg/m 2 showed inferior OS outcomes when compared to weekly 40 mg/m 2 ( P = 0.084) and triweekly 100 mg/m 2 ( P = 0.04) regimens. Conclusion: Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m 2, suggesting the inferiority of low‐dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m 2 chemotherapy regimens.